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The widening gap between cancer incidence and mortality
testifies to the increasing success of cancer treatment. For
example, in Queensland Australia, there are now more
than 7 cancer survivors for each patient newly diagnosed
with cancer. These individuals represent a population at
risk for recurrent malignancy for whom there is a growing
demand for imaging services.
Imaging for suspected recurrence may be prompted
by symptoms or rising tumour markers, whilst for
some tumours, imaging contributes to regular surveil-
lance. The benefits of early detection of recurrence
through imaging surveillance need to be balanced
against cost, patient anxiety and radiation exposure. A
recent study has estimated the absolute risk of second
cancer induction resulting from use of radiological
examinations in this context to be between 0.1% and
10% [1]. Targeting patients at greatest risk of recur-
rence would improve the balance between risk and
benefit for imaging surveillance and is potentially
achievable through the use of prognostic imaging bio-
markers derived from imaging procedures performed at
staging or post-treatment [2].
Increasingly sophisticated treatments for recurrent dis-
ease present further challenges to the use of imaging in
cancer survivorship. There are now more therapeutic
options for patients with localised disease or recurrence
to a few sites (oligometastatic disease). Although well
established for hepatic metastases from colorectal cancer,
surgical resection of localised recurrence is increasingly
adopted for alternative sites of recurrence and for other
tumour types. For tumour sites unamenable to surgery,
stereotactic body radiotherapy can allow focal delivery of
high-dose radiation with single or few fractions with pro-
mising local control and overall survival rates [3].
These developments create new questions for imaging.
Firstly, should imaging surveillance programmes of asymp-
tomatic cancer survivors be developed to allow identifica-
tion of the oligometastatic state prior to disseminated
disease? The potential benefits of surveillance are high-
lighted by a study of patterns of distant failure and progres-
sion in breast cancer which found oligometastatic disease
to be more common amongst asymptomatic patients [4].
Secondly, how can imaging be optimised to distinguish oli-
gometastatic from disseminated disease? Imaging in this
context must have high sensitivity and specificity on a
lesion-by-lesion basis because an accurate assessment of
the number of metastases is required to avoid the morbid-
ity of inappropriate oligometastatic treatment, as well as
the possibility of oligometastatic treatment being wrongly
withheld due to the presence of benign lesions that are
indistinguishable from additional metastases. Hybrid ima-
ging techniques that combine modalities with complemen-
tary sensitivity and specificity are likely to offer the greatest
opportunities for accurate assessment of oligometastatic
disease. Higher accuracy for skeletal metastases can be
achieved by diphosphonate SPECT/CT or fluoride PET/
CT in place of planar scintigraphy [5] whilst integrated
FDG-PET/MRI has the potential to optimise detection of
skeletal and hepatic recurrence in a single examination
[6,7]. The new PET tracer Gallium-68 Prostate Specific
Membrane Antigen demonstrates high accuracy for nodal
and skeletal recurrence prostate cancer [8].
Imaging protocols for cancer staging are now well
established. Increasing cancer survivorship has created a
need to develop equivalent protocols for the diagnosis
and assessment of tumour recurrence.
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